Efficacy and Safety of Fimasartan/Indapamide Combination Therapy versus Fimasartan Monotherapy in Patients with Essential Hypertension Inadequately Responding to Fimasartan 30 mg (FINEDUO): A Randomized, Double-Blind, Multicenter, Phase III Study Authors: Jong-Chan Youn, So-Young Lee, Cheol Woong Yu, Ki-Chul Sung, Jinho Shin, Ju Hyeon Oh, Jin Oh Na, Dae-Hee Kim, Eun Joo Cho, Hyuck-Jun Yoon, Chan Joo Lee, Han Cheol Lee, Hae-Young Lee, Il Suk Sohn, Kyu-Sun Lee, Doo Il Kim, Woong Gil Choi, Wook-Jin Chung, Eun Mi Lee, Seung-Hyuk Choi, Seonghoon Choi, Tae Soo Kang, Sang-Hyun Ihm Published: 2026 ABSTRACT PurposeEffective blood pressure (BP) control in hypertension frequently requires combination therapy, particularly in patients whose BP is inadequately controlled by monotherapy. This study evaluated the efficacy and safety of fimasartan (FMS) and indapamide (IND) sustained release (SR) combination therapy.Patients and MethodsIn this randomized, double-blind, phase III trial, patients with hypertension who remained uncontrolled after a 4-week run-in with FMS 30 mg, were randomized to FMS 30 mg/IND SR 1.5 mg or FMS 30 mg, followed by forced titration to FMS 60 mg/IND SR 1.5 mg or FMS 60 mg after 4 weeks. The primary endpoint was the change in sitting systolic BP (SiSBP) at week 8. Secondary endpoints included changes in sitting diastolic BP (SiDBP), BP control rates, response rates, and safety outcomes.ResultsTwo hundred forty-eight patients were randomized (FMS/IND SR, n=126; FMS, n=122). At week 8, the least square mean reduction in SiSBP was greater with FMS/IND SR than with FMS (−17.9 vs −7.4 mmHg, P<0.0001). Significant improvements were also observed for SiSBP at week 4, SiDBP at week 4 and 8, and BP control rates and response rates. The safety profile was comparable between groups, with no significant differences in adverse events, including patients aged 65 years and older.ConclusionFMS/IND SR combination therapy demonstrated superior antihypertensive efficacy, rapid BP control, and comparable safety to FMS monotherapy. This regimen may serve as an effective therapeutic option, particularly in elderly or high-risk hypertensive patients.Clinical Trial Registrationhttps://www.clinicaltrials.gov, NCT05878561. Introduction Effective blood pressure (BP) control often requires combination therapy, especially in patients whose hypertension is not adequately managed with monotherapy.1–4 Real-world data suggest that BP control with monotherapy is frequently suboptimal. In a real-life cohort of patients receiving monotherapy, only 36.6% of patients achieved office BP < 140/90 mmHg, and the control rate fell to 14.0% under the 2018 European Society of Cardiology/European Society of Hypertension targets. In another real-world study using both office and home BP criteria, only 6.7–8.5% of monotherapy-treated patients achieved BP control, indicating that the vast majority remained uncontrolled under more stringent assessment.5,6 Current guidelines recommend combining agents with complementary mechanisms of action, such as an angiotensin II receptor blocker (ARB) with either a calcium channel blocker or a thiazide-type diuretic, to enhance antihypertensive efficacy.1–4 Among these, ARB and diuretic combinations are especially effective in patients with resistant or salt-sensitive hypertension.7,8 This combination provides complementary BP-lowering effects by concurrently targeting the renin-angiotensin-aldosterone system (RAAS) and sodium/volume overload, yielding greater BP reductions than monotherapy. Moreover, ARBs can counteract the compensatory RAAS activation induced by diuretics and may attenuate metabolic adverse effects such as hypokalemia.9 ARB/HCTZ combinations are widely used and have consistently demonstrated greater BP lowering and higher target BP achievement than ARB monotherapy.10 Chlorthalidone-containing regimens may provide stronger and more sustained BP reduction, but their clinical use can be limited by a higher incidence of electrolyte abnormalities, particularly hypokalemia.11–13 These observations highlight the need to evaluate alternative thiazide-like diuretic components that may preserve antihypertensive potency while improving tolerability. Fimasartan (FMS) is a potent and highly selective ARB developed in Korea and currently used in many countries.14,15 Its antihypertensive efficacy at doses of 30–120 mg has been shown to be comparable to or greater than that of other ARBs, with a favorable safety profile.16–19 Indapamide (IND), a thiazide-like diuretic, exerts its BP-lowering effects through natriuresis in the distal renal tubules and direct vascular action.20 Several studies have demonstrated that IND and chlorthalidone are more effective than hydrochlorothiazide (HCTZ) in reducing BP.11,12,21 However, thiazide-like diuretics have been associated with an increased risk of electrolyte disturbances, such as hyponatremia and hypokalemia, especially at higher doses or in elderly patients. Chlorthalidone has shown a higher incidence of such abnormalities compared to HCTZ,13 and similar findings have been reported with the immediate release (IR) formulation of IND.22 The development of a sustained release (SR) formulation of IND has addressed these safety concerns. Compared with IND IR 2.5 mg, IND SR 1.5 mg provides a smoother 24-hour pharmacokinetic profile with lower peak plasma concentrations and has been associated with a lower incidence of hypokalemia while maintaining comparable antihypertensive efficacy in previous studies. Importantly, IND SR has also been shown to be effective and well tolerated in older patients.23–28 Given the high prevalence of salt-sensitive hypertension among elderly patients, IND SR may serve as an effective and well-tolerated therapeutic option. In addition to its BP-lowering effect, IND has demonstrated benefits in renal and cardiovascular outcomes and a neutral impact on glucose and lipid metabolism.29–34 Accordingly, several clinical guidelines recommend thiazide-like diuretics including IND over conventional thiazide for the management of hypertension.1,35 Given the potent antihypertensive efficacy of IND and the improved tolerability of its SR formulation, the combination of FMS and IND SR may provide greater BP reduction than FMS monotherapy while maintaining safety in patients with essential hypertension not adequately controlled with FMS monotherapy. However, the efficacy and safety of this combination therapy have not yet been investigated. Therefore, we conducted the clinical trial to evaluate the efficacy and safety of FMS/IND SR combination therapy in patients with essential hypertension who did not achieve target BP levels with FMS monotherapy. Methods Study Design The FINEDUO (FImasartan-INdapamide Effective DUO) was a randomized, double-blind, multicenter, phase III clinical study conducted at 22 clinical sites in Korea (Supplementary Table S1). The protocol was approved by the institutional review board of each participating clinical site and the Ministry of Food and Drug Safety. The study was conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice guideline. All patients provided written informed consent before undergoing any procedures. After voluntary agreement to participate in this study, all patients received FMS 30 mg during the wash out and the run-in period for 4 weeks. After the run-in period, patients were re-evaluated to confirm that they met the inclusion and exclusion criteria and were randomly assigned in a 1:1 ratio to receive either FMS 30mg/IND SR 1.5 mg (treatment group) or FMS 30 mg (control group). Patients were given the study drug once daily for 4 weeks, followed by forced dose titration to FMS 60mg/IND SR 1.5 mg or FMS 60 mg for 4 weeks (Figure 1). (ClinicalTrials.gov identifier: NCT05878561) Figure 1Summary of patient disposition.It presents patient disposition and the study schedule of the FINEDUO randomized, double-blind, multicenter, phase III trial. At visit 1, corresponding to screening at week minus 5, 511 patients were screened. Among them, 129 patients failed screening: 108 because of inclusion or exclusion criteria deviation, 14 because of withdrawal of consent, 4 because of adverse events, 1 because of prohibited medication or therapy, 1 because of loss to follow-up, and 1 for other reasons. A total of 382 patients entered the fimasartan 30 mg run-in period. During the run-in period, 134 patients failed to proceed to randomization. The reasons were inclusion or exclusion criteria deviation in 128 patients, including 113 patients who did not meet the blood pressure inclusion criteria due to blood pressure control, withdrawal of consent in 4 patients, adverse event in 1 patient, and prohibited medication or therapy in 1 patient. At visit 2, corresponding to baseline and randomization at week 0, 248 patients were randomized in a 1:1 ratio to either fimasartan plus indapamide sustained-release combination therapy or fimasartan monotherapy. In the combination-therapy group, 126 patients received fimasartan 30 mg plus indapamide sustained-release 1.5 mg from baseline to week 4. Before forced titration, 4 patients discontinued treatment: 2 because of withdrawal of consent, 1 because of signs of hypotension, and 1 because of inclusion or exclusion criteria deviation. At visit 3, corresponding to week 4, 122 patients underwent forced titration to fimasartan 60 mg plus indapamide sustained-release 1.5 mg. Between week 4 and visit 4, the end-of-study visit at week 8, 8 additional patients discontinued treatment: 1 because of withdrawal of consent, 1 because of signs of hypotension, 3 because of significant electrolyte imbalance, and 3 for other reasons. A total of 114 patients in the combination-therapy group completed the study. In the monotherapy group, 122 patients received fimasartan 30 mg from baseline to week 4. Before forced titration, 6 patients discontinued treatment: 2 because of withdrawal of consent, 1 because of prohibited medication or therapy, 2 because of inclusion or exclusion criteria deviation, and 1 for other reasons. At week 4, 116 patients underwent forced titration to fimasartan 60 mg. Between week 4 and the end-of-study visit at week 8, 9 additional patients discontinued treatment: 4 because of withdrawal of consent, 2 because of lack of efficacy, and 3 because of prohibited medication or therapy. A total of 107 patients in the monotherapy group completed the study.Flow diagram of patient disposition in the FINEDUO trial from screening through run-in, randomization, forced titration, and study completion. Of 511 screened patients, 382 entered the fimasartan run-in period, 248 were randomized to fimasartan/indapamide sustained-release combination therapy or fimasartan monotherapy, and 114 and 107 patients completed the study in the respective treatment groups.Abbreviations: FMS, fimasartan; IND, indapamide sustained release; BP, blood pressure; EOS, end of study. Summary of patient disposition. Patients Adults who were ≥ 19 years old with essential hypertension were included if they failed to respond after 4 weeks of FMS 30 mg, with their medication adherence of at least 70% during the run-in period. Hypertension was defined as mean sitting systolic BP (SiSBP) ≥ 140 mmHg and < 180 mmHg for those who had not taken antihypertensive medications prior to the screening visit. For those taking antihypertensive medications, hypertension was defined as mean SiSBP ≥ 130 mmHg and < 180 mmHg. Participants were excluded from the study if they had secondary hypertension, severe hypertension (SiSBP ≥ 180 mmHg or sitting diastolic BP (SiDBP) ≥ 110 mmHg), symptomatic orthostatic hypotension, heart failure (New York Heart Association Class III and IV), significant structural heart disease or arrhythmia, clinically relevant or unstable cardiovascular diseases (CVDs) within 6 months prior to the screening visit, uncontrolled diabetes mellitus (DM, glycosylated hemoglobin level > 9%), or were taking three or more antihypertensive drugs of different classes. Only patients receiving fewer than three antihypertensive drug classes were eligible for enrollment. Participants were withdrawn from the study if any of the following criteria were met: withdrawal of consent, occurrence of clinically significant adverse drug reactions (ADRs, including hypersensitivity), clinically significant abnormalities in BP or laboratory parameters (eg, elevated alanine aminotransferase, aspartate aminotransferase or decreased estimated glomerular filtration rate (eGFR) or decreased serum potassium, sodium), violation of key inclusion/exclusion criteria, pregnancy, use of prohibited concomitant medications, loss to follow-up, or at the investigator’s discretion. Randomization and Masking Randomization was performed using a stratified block method, with clinical sites as the stratification factor. An independent statistician generated the randomization sequence using SAS version 9.4, and participants were centrally assigned to treatment groups via an interactive web response system for randomization and study drug management. Sponsor prepared and labeled the study drugs in accordance with the randomization list, and the study drugs were packaged for the treatment and control groups. To maintain double-blinding, identical labeling was applied to the outer packaging of all study drugs, including the placebo. This ensured that participants and investigators were kept blinded to group allocation during the treatment period. Moreover, access to the randomization codes of study drugs were strictly controlled, and the codes were disclosed only after trial completion, following the data lock and unblinding procedures. Efficacy and Safety Evaluation The primary endpoint was the change in SiSBP from baseline to week 8. The secondary endpoints were the change in SiSBP from baseline to week 4, the changes in SiDBP from baseline to week 4 and 8, the BP control rates (the proportion of participants who achieved SiSBP/SiDBP < 130/80 mmHg for patients with CVD, DM or chronic kidney disease (CKD) with albuminuria, SiSBP/SiDBP < 140/90 mmHg for the others) and response rates (the proportion of participants with a decrease in SiSBP ≥ 20 mmHg or SiDBP ≥ 10 mmHg) at week 4 and 8. At each visit, BP was measured three times with at least 2-minute intervals using a validated automated BP monitor (UA-1020, A&D Company, Ltd., Tokyo, Japan) after at least 5 minutes of rest in a seated position. The mean of the three BP measurements was calculated. At the screening visit, BP was measured in both arms, and the arm with the higher mean SiSBP was designated as the reference arm for subsequent visits. If mean SiSBP was equal, the arm with higher mean SiDBP was designated as the reference arm. To ensure consistency, all subsequent measurements were performed on the same arm. Participants were instructed to avoid caffeine intake, smoking, and strenuous exercise for at least 30 minutes prior to BP measurement. The safety assessment was based on the incidence of treatment emergent adverse events (TEAEs) observed on physical examinations, laboratory tests, vital signs, and electrocardiogram. TEAEs were defined as AEs that occurred on or after the first administration of the study drug. ADRs were defined as TEAEs for which a causal relationship with the study drug could not be ruled out, as assessed by the investigator using predefined causality categories. Laboratory tests were performed at screening, baseline, and each scheduled visit (weeks 4 and 8) to monitor participant safety. Abnormal laboratory values, including hypokalemia and hyponatremia, were initially identified based on the local laboratory reference ranges at each clinical site and classified as AEs by the investigators. Medication adherence was assessed at baseline and each subsequent visit by using pill counts, based on the number of study drugs dispensed and returned. Statistical Analysis Because no previous studies have evaluated the effects of the combination therapy on BP, the expected difference in mean change and standard deviation (SD) were conservatively estimated based on pooled results from published studies of similar combination therapies.36–38 The estimated difference in the reduction in SiSBP between the FMS/IND SR group and the FMS group was 5.5 mmHg with SD of 14 mmHg. Sample size was calculated using a two-sided, two-sample t-test assuming equal variance, with 80% statistical power and a 5% significance level. This calculation indicated that 103 participants per group were required for a 1:1 randomization. With a dropout rate of 15%, the total number of participants was determined to be 244. This study was conducted in accordance with the intention-to-treat principle. Efficacy data were primarily analyzed in the full analysis set (FAS), which included all randomized patients who received at least one dose of the study drug and had at least one efficacy assessment after baseline, and also in the per-protocol set (PPS). The primary and secondary endpoints (except the BP control rates and response rates) were compared using an analysis of covariance with the baseline value as a covariate. The BP control rates and response rates were analyzed using logistic regression model with the baseline BPs as covariates. Safety was assessed in patients who received at least one dose of the study drug (safety set). For safety assessment, the difference in the incidence of TEAEs and ADRs between the two groups was assessed using the chi-square test or Fisher’s exact test. No statistical adjustment was made for multiplicity arising from multiple comparisons or tests. Missing outcome data due to loss to follow‑up or early treatment discontinuation were handled according to predefined statistical analysis plan. For FAS analyses, missing data were imputed using the last observation carried forward (LOCF) method, including measurements from unscheduled visits when available. If LOCF was not applicable, observed data were analyzed without imputation. For PPS analyses and all safety endpoints, no imputation was performed, and observed data were analyzed as recorded. Subgroup analyses were conducted to assess the consistency of primary endpoint and safety outcomes using the same statistical methods as those applied to the primary endpoint and safety outcomes. Subgroup analyses were performed to evaluate the primary endpoint according to the following baseline factors: age (< 65 or ≥ 65 years), sex (male or female), body mass index (< 25 or ≥ 25 kg/m2), drinking status (current non-drinker or current drinker), smoking status (non-smoker, current smoker or ex-smoker), duration of essential hypertension (< 5 or ≥ 5, < 10 or ≥ 10 years), baseline systolic BP (SBP) and diastolic BP (DBP) (each categorized into two groups based on the observed median: < 147 or ≥ 147 mmHg for SBP, and < 93 or ≥ 93 mmHg for DBP), and the presence of comorbidities (DM: clinical history of diabetes and antidiabetic medication use, or HbA1c ≥ 6.5% at screening; dyslipidemia; CKD: clinical history of CKD or eGFR < 90 mL/min/1.73 m2 at baseline; coronary artery disease (CAD)). In addition, a subgroup analysis by age (< 65 or ≥ 65 years) was performed for the safety. All statistical analyses were performed using SAS software version 9.4 (SAS Institute Inc, Cary, North Carolina). Results Patients A total of 511 patients were screened, and 248 patients were randomized to receive either FMS/IND SR (n=126) or FMS (n=122). Of randomized patients, 221 patients completed the study (Figure 1). Two hundred forty-one patients were evaluated for efficacy and 244 patients for safety. The demographic and baseline characteristics were well balanced between the two groups (Table 1).Table 1Demographic and Baseline Characteristics (Full Analysis Set)CharacteristicFMS/IND(N=124)FMS(N=117)P-valueAge (years) Mean (SD)61.69 (12.87)62.36 (11.85)0.6517a Subgroup, n (%)0.3347b <6566 (53.23)55 (47.01) ≥6558 (46.77)62 (52.99)Sex, n (%)0.9834b Male86 (69.35)81 (69.23) Female38 (30.65)36 (30.77)Weight (kg) Mean (SD)72.84 (13.90)72.04 (13.65)0.6978aBMIc (kg/m²) Mean (SD)26.65 (3.75)26.33 (3.91)0.5804a Subgroup, n (%)0.5387b <2544 (35.48)46 (39.32) ≥2580 (64.52)71 (60.68)Drinking status, n (%)0.7230b Current non-drinker46 (37.10)46 (39.32) Current drinker78 (62.90)71 (60.68)Smoking status, n (%)0.9595b Non-smoker61 (49.19)59 (50.43) Current smoker24 (19.35)21 (17.95) Ex-smoker39 (31.45)37 (31.62)Duration of essential hypertensiond (years) Mean (SD)9.31 (9.13)8.13 (7.35)0.5535a Subgroup, n (%)0.4628b <555 (44.35)48 (41.03) ≥5, <1017 (13.71)23 (19.66) ≥1052 (41.94)46 (39.32)SBP at baseline (mmHg) Mean (SD)150.65 (10.54)151.52 (11.08)0.5572a Median147.15147.70 Subgroup, n (%)0.7344b <14761 (49.19)55 (47.01) ≥14763 (50.81)62 (52.99)DBP at baseline (mmHg) Mean (SD)92.36 (9.41)93.82 (8.45)0.2657a Median92.3094.00 Subgroup, n (%)0.3270b <9364 (51.61)53 (45.30) ≥9360 (48.39)64 (54.70)eGFRe (mL/min/1.73m2) Mean (SD)87.78 (16.44)87.78 (15.29)0.9124a Median89.8290.00Diabetes mellitus, n (%)0.9546b Yes29 (23.39)27 (23.08) No95 (76.61)90 (76.92)Dyslipidemia, n (%)0.5760b Yes73 (58.87)73 (62.39) No51 (41.13)44 (37.61)Chronic kidney disease, n (%)0.7459b Yes63 (50.81)57 (48.72) No61 (49.19)60 (51.28)Coronary artery disease, n (%)0.8946b Yes22 (17.74)20 (17.09) No102 (82.26)97 (82.91)Notes: aTesting for difference between-treatment groups (two sample t-test or Wilcoxon rank sum test). bTesting for difference between-treatment groups (chi-square test or Fisher’s exact test). cBMI (kg/m²) = weight (kg) / (height (cm) / 100)². dDuration of essential hypertension (years) = (visit 1 - diagnosis date + 1) / 365.25. eeGFR was calculated using the CKD-EPI equation.Abbreviations: FMS, fimasartan; IND, indapamide sustained release; SD, standard deviation; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate. Table 1Demographic and Baseline Characteristics (Full Analysis Set)CharacteristicFMS/IND(N=124)FMS(N=117)P-valueAge (years) Mean (SD)61.69 (12.87)62.36 (11.85)0.6517a Subgroup, n (%)0.3347b <6566 (53.23)55 (47.01) ≥6558 (46.77)62 (52.99)Sex, n (%)0.9834b Male86 (69.35)81 (69.23) Female38 (30.65)36 (30.77)Weight (kg) Mean (SD)72.84 (13.90)72.04 (13.65)0.6978aBMIc (kg/m²) Mean (SD)26.65 (3.75)26.33 (3.91)0.5804a Subgroup, n (%)0.5387b <2544 (35.48)46 (39.32) ≥2580 (64.52)71 (60.68)Drinking status, n (%)0.7230b Current non-drinker46 (37.10)46 (39.32) Current drinker78 (62.90)71 (60.68)Smoking status, n (%)0.9595b Non-smoker61 (49.19)59 (50.43) Current smoker24 (19.35)21 (17.95) Ex-smoker39 (31.45)37 (31.62)Duration of essential hypertensiond (years) Mean (SD)9.31 (9.13)8.13 (7.35)0.5535a Subgroup, n (%)0.4628b <555 (44.35)48 (41.03) ≥5, <1017 (13.71)23 (19.66) ≥1052 (41.94)46 (39.32)SBP at baseline (mmHg) Mean (SD)150.65 (10.54)151.52 (11.08)0.5572a Median147.15147.70 Subgroup, n (%)0.7344b <14761 (49.19)55 (47.01) ≥14763 (50.81)62 (52.99)DBP at baseline (mmHg) Mean (SD)92.36 (9.41)93.82 (8.45)0.2657a Median92.3094.00 Subgroup, n (%)0.3270b <9364 (51.61)53 (45.30) ≥9360 (48.39)64 (54.70)eGFRe (mL/min/1.73m2) Mean (SD)87.78 (16.44)87.78 (15.29)0.9124a Median89.8290.00Diabetes mellitus, n (%)0.9546b Yes29 (23.39)27 (23.08) No95 (76.61)90 (76.92)Dyslipidemia, n (%)0.5760b Yes73 (58.87)73 (62.39) No51 (41.13)44 (37.61)Chronic kidney disease, n (%)0.7459b Yes63 (50.81)57 (48.72) No61 (49.19)60 (51.28)Coronary artery disease, n (%)0.8946b Yes22 (17.74)20 (17.09) No102 (82.26)97 (82.91)Notes: aTesting for difference between-treatment groups (two sample t-test or Wilcoxon rank sum test). bTesting for difference between-treatment groups (chi-square test or Fisher’s exact test). cBMI (kg/m²) = weight (kg) / (height (cm) / 100)². dDuration of essential hypertension (years) = (visit 1 - diagnosis date + 1) / 365.25. eeGFR was calculated using the CKD-EPI equation.Abbreviations: FMS, fimasartan; IND, indapamide sustained release; SD, standard deviation; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate. Demographic and Baseline Characteristics (Full Analysis Set) Notes: aTesting for difference between-treatment groups (two sample t-test or Wilcoxon rank sum test). bTesting for difference between-treatment groups (chi-square test or Fisher’s exact test). cBMI (kg/m²) = weight (kg) / (height (cm) / 100)². dDuration of essential hypertension (years) = (visit 1 - diagnosis date + 1) / 365.25. eeGFR was calculated using the CKD-EPI equation. Abbreviations: FMS, fimasartan; IND, indapamide sustained release; SD, standard deviation; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate. Blood Pressure-Lowering Effect After 8 weeks of treatment, the mean (SD) change in SiSBP was −17.7 (16.0) mmHg in the FMS/IND SR and −7.6 (16.3) mmHg in the FMS (all P < 0.0001). The least square (LS) mean difference (standard error (SE)) between the two groups was −10.5 (2.0) mmHg (P < 0.0001), indicating that BP-lowering effect of FMS/IND SR combination therapy was superior to that of FMS monotherapy at week 8. Similar findings were also observed at week 4. The mean (SD) change in SiSBP at week 4 was −15.1 (15.1) mmHg in the FMS/IND SR and −5.3 (14.2) mmHg in the FMS (P < 0.0001 and P = 0.0001, respectively). The LS mean difference (SE) between the two groups was −10.2 (1.8) mmHg (P < 0.0001). Furthermore, the LS mean changes in SiDBP from baseline to week 4 and 8 were significantly greater in the FMS/IND SR than in the FMS (all P < 0.0001) (Table 2 and Figure 2).Table 2Change in Blood Pressure From Baseline to week 4 and 8 (Full Analysis Set)VariableFMS/IND(N=124)FMS(N=117)P-valueSiSBP, mmHg Baseline (week 0)150.7 (10.5)151.5 (11.1)0.5572a At week 4135.7 (13.7)146.3 (14.9) LS mean change (SE)−15.3 (1.2)−5.0 (1.3) Difference (95% CI) vs FMS−10.2 (−13.7 to −6.8)-<0.0001b At week 8132.9 (14.9)143.9 (17.9) LS mean change (SE)−17.9 (1.4)−7.4 (1.4) Difference (95% CI) vs FMS−10.5 (−14.4 to −6.6)-<0.0001bSiDBP, mmHg Baseline (week 0)92.4 (9.4)93.8 (8.5)0.2657a At week 486.4 (9.3)92.2 (9.4) LS mean change (SE)−6.0 (0.7)−1.2 (0.7) Difference (95% CI) vs FMS−4.8 (−6.7 to −2.9)-<0.0001b At week 885.1 (9.5)90.8 (10.8) LS mean change (SE)−7.5 (0.7)−2.8 (0.8) Difference (95% CI) vs FMS−4.7 (−6.8 to −2.6)-<0.0001bNotes: Values are presented as the mean (SD). aTesting for difference between treatment groups (Wilcoxon rank sum test). bTesting for difference between treatment groups (ANCOVA model with baseline BP as a covariate).Abbreviations: FMS, fimasartan; IND, indapamide sustained release; SiSBP, sitting systolic blood pressure; SE, standard error; CI, confidence interval; SiDBP, sitting diastolic blood pressure; LS, least square; SD, standard deviation; ANCOVA, analysis of covariance. Figure 2Mean SiSBP (A) and SiDBP (B) from baseline to week 4 and 8.Two-panel line graph illustrating changes in mean sitting systolic and diastolic blood pressure from baseline to weeks 4 and 8 in patients randomized to fimasartan/indapamide sustained-release combination therapy or fimasartan monotherapy. The solid line with filled circles represents the fimasartan/indapamide sustained-release group, and the dashed line with open diamonds represents the fimasartan monotherapy group. Panel A shows mean sitting systolic blood pressure. At baseline, mean sitting systolic blood pressure was 150.7 mmHg in the fimasartan/indapamide sustained-release group and 151.5 mmHg in the fimasartan group. At week 4, mean sitting systolic blood pressure decreased to 135.7 mmHg in the combination-therapy group and to 146.3 mmHg in the monotherapy group. At week 8, mean sitting systolic blood pressure further decreased to 132.9 mmHg in the combination-therapy group and to 143.9 mmHg in the monotherapy group. The between-group differences at weeks 4 and 8 were statistically significant, with P < 0.0001. Panel B shows mean sitting diastolic blood pressure. At baseline, mean sitting diastolic blood pressure was 92.4 mmHg in the fimasartan/indapamide sustained-release group and 93.8 mmHg in the fimasartan group. At week 4, mean sitting diastolic blood pressure decreased to 86.4 mmHg in the combination-therapy group and to 92.2 mmHg in the monotherapy group. At week 8, mean sitting diastolic blood pressure further decreased to 85.1 mmHg in the combination-therapy group and to 90.8 mmHg in the monotherapy group. The between-group differences at weeks 4 and 8 were statistically significant, with P < 0.0001. Overall, the figure demonstrates more rapid and greater reductions in both sitting systolic and diastolic blood pressure with fimasartan/indapamide sustained-release combination therapy compared with fimasartan monotherapy.Two-panel line graph showing mean sitting systolic and diastolic blood pressure from baseline to weeks 4 and 8.Notes: Statistical analyses are performed using analysis of covariance (ANCOVA) with baseline values as covariates to compare changes between treatment groups at each time point. The number of participants is n = 124 for the FMS/IND group and n = 117 for the FMS group. The FMS/IND group is represented by filled circles (●), and the FMS group is represented by open diamonds (◇). Statistical significance is indicated as follows: ****P < 0.0001.Abbreviations: FMS, fimasartan; IND, indapamide sustained release; SiSBP, sitting systolic blood pressure; SiDBP, sitting diastolic blood pressure. Table 2Change in Blood Pressure From Baseline to week 4 and 8 (Full Analysis Set)VariableFMS/IND(N=124)FMS(N=117)P-valueSiSBP, mmHg Baseline (week 0)150.7 (10.5)151.5 (11.1)0.5572a At week 4135.7 (13.7)146.3 (14.9) LS mean change (SE)−15.3 (1.2)−5.0 (1.3) Difference (95% CI) vs FMS−10.2 (−13.7 to −6.8)-<0.0001b At week 8132.9 (14.9)143.9 (17.9) LS mean change (SE)−17.9 (1.4)−7.4 (1.4) Difference (95% CI) vs FMS−10.5 (−14.4 to −6.6)-<0.0001bSiDBP, mmHg Baseline (week 0)92.4 (9.4)93.8 (8.5)0.2657a At week 486.4 (9.3)92.2 (9.4) LS mean change (SE)−6.0 (0.7)−1.2 (0.7) Difference (95% CI) vs FMS−4.8 (−6.7 to −2.9)-<0.0001b At week 885.1 (9.5)90.8 (10.8) LS mean change (SE)−7.5 (0.7)−2.8 (0.8) Difference (95% CI) vs FMS−4.7 (−6.8 to −2.6)-<0.0001bNotes: Values are presented as the mean (SD). aTesting for difference between treatment groups (Wilcoxon rank sum test). bTesting for difference between treatment groups (ANCOVA model with baseline BP as a covariate).Abbreviations: FMS, fimasartan; IND, indapamide sustained release; SiSBP, sitting systolic blood pressure; SE, standard error; CI, confidence interval; SiDBP, sitting diastolic blood pressure; LS, least square; SD, standard deviation; ANCOVA, analysis of covariance. Change in Blood Pressure From Baseline to week 4 and 8 (Full Analysis Set) Notes: Values are presented as the mean (SD). aTesting for difference between treatment groups (Wilcoxon rank sum test). bTesting for difference between treatment groups (ANCOVA model with baseline BP as a covariate). Abbreviations: FMS, fimasartan; IND, indapamide sustained release; SiSBP, sitting systolic blood pressure; SE, standard error; CI, confidence interval; SiDBP, sitting diastolic blood pressure; LS, least square; SD, standard deviation; ANCOVA, analysis of covariance. Mean SiSBP (A) and SiDBP (B) from baseline to week 4 and 8. The BP control rates and response rates at week 4 and 8 in the FMS/IND SR and the FMS are shown in Figure 3. These rates of the FMS/IND SR were significantly higher than those of the FMS, both at week 4 and 8. Similar results were confirmed in terms of BP control rates according to target BP values of < 140/90 and < 130/80 mmHg regardless of comorbidities (Figure 4). Figure 3Blood pressure control rates (A) and response rates (B) from baseline to week 4 and 8.Two-panel grouped bar graph comparing blood pressure control rates and response rates at weeks 4 and 8 in patients randomized to fimasartan/indapamide sustained-release combination therapy or fimasartan monotherapy. Black bars represent the fimasartan/indapamide sustained-release group, and white bars represent the fimasartan monotherapy group. Blood pressure control rate was defined as the proportion of patients achieving sitting systolic blood pressure below 140 mmHg and sitting diastolic blood pressure below 90 mmHg, or below 130/80 mmHg for patients with cardiovascular disease, diabetes mellitus, or chronic kidney disease with albuminuria. Response rate was defined as the proportion of patients with a reduction in sitting systolic blood pressure of at least 20 mmHg or sitting diastolic blood pressure of at least 10 mmHg. Panel A shows blood pressure control rates. At week 4, the control rate was 43.55% in the fimasartan/indapamide sustained-release group and 19.66% in the fimasartan group. At week 8, the control rate increased to 52.42% in the fimasartan/indapamide sustained-release group and 26.50% in the fimasartan group. The between-group differences were statistically significant at both week 4 and week 8, with p < 0.001 and p < 0.0001, respectively. Panel B shows blood pressure response rates. At week 4, the response rate was 43.55% in the fimasartan/indapamide sustained-release group and 21.37% in the fimasartan group. At week 8, the response rate was 51.61% in the fimasartan/indapamide sustained-release group and 29.06% in the fimasartan group. The between-group differences were statistically significant at both time points, with p < 0.0001. Overall, the figure demonstrates that fimasartan/indapamide sustained-release combination therapy resulted in higher rates of blood pressure control and treatment response than fimasartan monotherapy at both week 4 and week 8.Two-panel grouped bar graph showing blood pressure control rates and response rates at weeks 4 and 8. Fimasartan/indapamide sustained-release combination therapy achieved significantly higher control and response rates than fimasartan monotherapy at both time points.Notes: The control rate is defined as SiSBP < 140 mmHg and SiDBP < 90 mmHg (SiSBP < 130 mmHg and SiDBP < 80 mmHg for the patients with CVD, DM, CKD with albuminuria). The response rate is defined as a fall in SiSBP ≥ 20mmHg or SiDBP ≥ 10mmHg. Data are presented as the proportion (%) of participants achieving the target at week 4 and 8. The number of participants is n = 124 for the FMS/IND group and n = 117 for the FMS group. Testing for between treatment groups: Logistic regression model with treatment group as a factor and baseline value as covariates at each time point. Statistical significance is indicated as follows: ***P < 0.001, ****P < 0.0001.Abbreviations: CKD, Chronic Kidney Disease; CVD, cardiovascular disease; DM, Diabetes Mellitus; FMS, fimasartan; IND, indapamide sustained release; SiSBP, sitting systolic blood pressure; SiDBP, sitting diastolic blood pressure. Figure 4Blood pressure control rates < 140/90 mmHg (A) and control rates < 130/80 mmHg (B) regardless of comorbidities from baseline to week 4 and 8.Two-panel grouped bar graph comparing blood pressure control rates at weeks 4 and 8 in patients randomized to fimasartan/indapamide sustained-release combination therapy or fimasartan monotherapy. Black bars represent the fimasartan/indapamide sustained-release group, and white bars represent the fimasartan monotherapy group. The control rates are presented according to two blood pressure thresholds, regardless of comorbidities. Panel A shows the proportion of patients achieving blood pressure control below 140/90 mmHg. At week 4, the control rate was 45.97% in the fimasartan/indapamide sustained-release group and 25.64% in the fimasartan group. At week 8, the control rate increased to 58.06% in the fimasartan/indapamide sustained-release group and 34.19% in the fimasartan group. The between-group differences were statistically significant at both week 4 and week 8, with p < 0.01 and p < 0.001, respectively. Panel B shows the proportion of patients achieving blood pressure control below 130/80 mmHg. At week 4, the control rate was 16.94% in the fimasartan/indapamide sustained-release group and 2.56% in the fimasartan group. At week 8, the control rate was 18.55% in the fimasartan/indapamide sustained-release group and 6.84% in the fimasartan group. The between-group differences were statistically significant at both week 4 and week 8, with p < 0.01 and p < 0.05, respectively. Overall, the figure demonstrates that fimasartan/indapamide sustained-release combination therapy achieved higher blood pressure control rates than fimasartan monotherapy at both the <140/90 mmHg and <130/80 mmHg thresholds.Two-panel grouped bar graph showing blood pressure control rates using thresholds of <140/90 mmHg and <130/80 mmHg at weeks 4 and 8, regardless of comorbidities. Fimasartan/indapamide sustained-release combination therapy achieved significantly higher control rates than fimasartan monotherapy at both thresholds and both time points.Notes: The control rate is defined, regardless of comorbidities, as SiSBP < 140 mmHg and SiDBP < 90 mmHg for Graph A, and SiSBP < 130 mmHg and SiDBP < 80 mmHg for Graph B. Data are presented as the proportion (%) of participants achieving the target at week 4 and 8. The number of participants is n = 124 for the FMS/IND group and n = 117 for the FMS group. Testing for between treatment groups: Logistic regression model with treatment group as a factor and baseline value as covariates at each time point. Statistical significance is indicated as follows: *P < 0.05, **P < 0.01, ***P < 0.001.Abbreviations: FMS, fimasartan; IND, indapamide sustained release; SiSBP, sitting systolic blood pressure; SiDBP, sitting diastolic blood pressure. Blood pressure control rates (A) and response rates (B) from baseline to week 4 and 8. Blood pressure control rates < 140/90 mmHg (A) and control rates < 130/80 mmHg (B) regardless of comorbidities from baseline to week 4 and 8. Additionally, results of all subgroup analyses of the primary endpoint were consistent with those in the overall study population including patients aged 65 and older (Table 3 and Figure 5).Table 3Change in SiSBP From Baseline to week 8 According to Subgroup Analyses (Full Analysis Set)SubgroupaFMS/INDFMSLS Mean Differenceb(95% CI)vs FMSNBaseline(Week 0)At Week 8NBaseline(Week 0)At Week 8Overall124150.7 (10.5)133.0 (14.9)117151.5 (11.1)144.0 (17.9)−10.5 (−14.4 to −6.6)Age Group (years) <6566149.7 (9.1)131.3 (14.1)55150.3 (10.5)141.6 (16.0)−10.1 (−15.4 to −4.8) ≥6558151.7 (12.0)134.9 (15.6)62152.6 (11.6)146.0 (19.3)−10.6 (−16.4 to −4.8)Sex Male86149.8 (9.5)134.4 (15.4)81150.8 (9.7)145.7 (17.9)−10.7 (−15.5 to −6.0) Female38152.5 (12.5)129.7 (13.0)36153.1 (13.6)139.9 (17.6)−9.9 (−16.5 to −3.3)BMIc (kg/m2) <2544151.4 (11.1)133.3 (16.3)46150.2 (11.2)143.6 (18.1)−11.0 (−17.7 to −4.4) ≥2580150.3 (10.3)132.7 (14.1)71152.4 (11.0)144.2 (17.9)−10.4 (−15.3 to −5.5)Drinking status Current non-drinker46151.7 (11.6)130.4 (14.3)46153.6 (12.1)144.7 (19.4)−13.4 (−20.2 to −6.6) Current drinker78150.0 (9.9)134.4 (15.0)71150.1 (10.2)143.4 (17.0)−9.0 (−13.7 to −4.2)Smoking status Non-smoker61151.5 (11.6)131.5 (14.5)59151.8 (11.6)141.8 (19.5)−10.1 (−15.9 to −4.4) Current smoker24150.7 (8.5)133.9 (17.2)21151.5 (10.3)146.0 (15.3)−12.1 (−22.1 to −2.1) Ex-smoker39149.3 (10.1)134.6 (14.0)37151.2 (11.0)146.2 (16.5)−10.3 (−16.6 to −4.0)Duration of essential hypertension (years) <555149.5 (9.5)131.3 (14.8)48149.3 (10.5)141.3 (16.0)−10.0 (−15.8 to −4.3) ≥5, <1017149.3 (11.9)130.0 (18.7)23153.2 (11.3)144.9 (17.2)−11.9 (−22.2 to −1.6) ≥1052152.3 (11.1)135.6 (13.3)46153.0 (11.5)146.3 (20.0)−10.3 (−16.8 to −3.9)SBP at baseline (mmHg) <14761142.0 (3.8)129.4 (13.8)55142.5 (3.6)136.5 (14.5)−6.8 (−12.0 to −1.6) ≥14763159.0 (7.9)136.4 (15.1)62159.5 (9.2)150.6 (18.1)−14.0 (−19.8 to −8.2)DBP at baseline (mmHg) <9364148.7 (10.7)133.7 (15.6)53148.1 (9.8)142.3 (15.3)−8.9 (−14.1 to −3.7) ≥9360152.7 (10.0)132.1 (14.1)64154.3 (11.4)145.3 (19.8)−12.5 (−18.4 to −6.5)Diabetes mellitus Yes29153.7 (10.7)138.7 (15.3)27150.6 (11.8)140.9 (19.6)−3.7 (−12.8 to 5.4) No95149.7 (10.4)131.2 (14.3)90151.8 (10.9)144.8 (17.4)−12.5 (−16.9 to −8.2)Dyslipidemia Yes73150.7 (11.6)132.1 (14.2)73150.1 (11.0)141.2 (16.8)−9.3 (−14.1 to −4.4) No51150.6 (8.9)134.1 (15.8)44153.9 (11.0)148.6 (19.0)−12.2 (−18.9 to −5.6)Chronic kidney disease Yes63152.0 (11.7)134.6 (15.1)57151.4 (11.1)144.9 (19.4)−10.7 (−16.6 to −4.7) No61149.2 (9.1)131.3 (14.5)60151.7 (11.1)143.0 (16.5)−10.4 (−15.7 to −5.1)Coronary artery disease Yes22151.0 (12.0)132.1 (11.3)20146.1 (11.0)142.2 (14.8)−11.7 (−19.7 to −3.7) No102150.6 (10.3)133.1 (15.6)97152.6 (10.8)144.3 (18.5)−10.0 (−14.5 to −5.5)Notes: Values are presented as the mean (SD). aNo significant interaction effects were observed for subgroups of baseline factor. bTesting for difference between treatment groups (ANCOVA model with baseline SiSBP as a covariate). cBMI (kg/m²) = weight (kg) / (height (cm) / 100)².Abbreviations: SiSBP, sitting systolic blood pressure; FMS, fimasartan; IND, indapamide sustained release; LS, least square; CI, confidence interval; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; SD, standard deviation; ANCOVA, analysis of covariance. Figure 5Forest plot of subgroup analyses for comparison of FMS/IND combination therapy and FMS monotherapy of the changes in SiSBP from baseline to week 8.Forest plot presenting subgroup analyses of the least-squares mean change in sitting systolic blood pressure from baseline to week 8 in patients randomized to fimasartan/indapamide sustained-release combination therapy or fimasartan monotherapy. The table columns show the subgroup, least-squares mean change with standard error for each treatment group, least-squares mean difference, 95% confidence interval, and P value. Negative values indicate reductions in sitting systolic blood pressure. The vertical reference line at zero represents no between-group difference; estimates to the left of zero favor fimasartan/indapamide sustained-release, and estimates to the right favor fimasartan monotherapy. In the overall population, sitting systolic blood pressure decreased by 17.9 mmHg in the fimasartan/indapamide sustained-release group and by 7.4 mmHg in the fimasartan group. The least-squares mean difference was −10.5 mmHg, with a 95% confidence interval from −14.4 to −6.6, and P < 0.0001. Across age subgroups, the least-squares mean difference was −10.1 mmHg in patients younger than 65 years and −10.6 mmHg in patients aged 65 years or older. By sex, the difference was −10.7 mmHg in men and −9.9 mmHg in women. By body mass index, the difference was −11.0 mmHg in patients with body mass index below 25 kg/m² and −10.4 mmHg in those with body mass index of 25 kg/m² or higher. These results favored fimasartan/indapamide sustained-release in each subgroup. By drinking status, the least-squares mean difference was −13.4 mmHg in current non-drinkers and −9.0 mmHg in current drinkers. By smoking status, the difference was −10.1 mmHg in non-smokers, −12.1 mmHg in current smokers, and −10.3 mmHg in ex-smokers. By duration of essential hypertension, the difference was −10.0 mmHg for less than 5 years, −11.9 mmHg for 5 to less than 10 years, and −10.3 mmHg for 10 years or longer. By baseline blood pressure, the least-squares mean difference was −6.8 mmHg in patients with baseline systolic blood pressure below 147 mmHg and −14.0 mmHg in those with baseline systolic blood pressure of 147 mmHg or higher. For baseline diastolic blood pressure, the difference was −8.9 mmHg in patients below 93 mmHg and −12.5 mmHg in those with 93 mmHg or higher. By comorbidity status, the least-squares mean difference was −3.7 mmHg in patients with diabetes mellitus and −12.5 mmHg in patients without diabetes mellitus. For dyslipidemia, the difference was −9.3 mmHg in patients with dyslipidemia and −12.2 mmHg in those without dyslipidemia. For chronic kidney disease, the difference was −10.7 mmHg in patients with chronic kidney disease and −10.4 mmHg in those without chronic kidney disease. For coronary artery disease, the difference was −11.7 mmHg in patients with coronary artery disease and −10.0 mmHg in those without coronary artery disease. Overall, the forest plot shows that fimasartan/indapamide sustained-release combination therapy produced greater reductions in sitting systolic blood pressure than fimasartan monotherapy across all predefined subgroups, with point estimates consistently favoring the combination therapy.Forest plot of subgroup analyses comparing changes in sitting systolic blood pressure from baseline to week 8 between fimasartan/indapamide sustained-release combination therapy and fimasartan monotherapy. The treatment effect favored fimasartan/indapamide sustained-release across all predefined subgroups, with most subgroup comparisons showing statistically significant greater blood pressure reductions.Note: Values are presented as the LS mean change (SE).Abbreviations: BMI, body mass index; CI, confidence interval; DBP, diastolic blood pressure; FMS, fimasartan; IND, indapamide sustained release; LS, least square; SBP, systolic blood pressure; SE, standard error; SiSBP, sitting systolic blood pressure. Table 3Change in SiSBP From Baseline to week 8 According to Subgroup Analyses (Full Analysis Set)SubgroupaFMS/INDFMSLS Mean Differenceb(95% CI)vs FMSNBaseline(Week 0)At Week 8NBaseline(Week 0)At Week 8Overall124150.7 (10.5)133.0 (14.9)117151.5 (11.1)144.0 (17.9)−10.5 (−14.4 to −6.6)Age Group (years) <6566149.7 (9.1)131.3 (14.1)55150.3 (10.5)141.6 (16.0)−10.1 (−15.4 to −4.8) ≥6558151.7 (12.0)134.9 (15.6)62152.6 (11.6)146.0 (19.3)−10.6 (−16.4 to −4.8)Sex Male86149.8 (9.5)134.4 (15.4)81150.8 (9.7)145.7 (17.9)−10.7 (−15.5 to −6.0) Female38152.5 (12.5)129.7 (13.0)36153.1 (13.6)139.9 (17.6)−9.9 (−16.5 to −3.3)BMIc (kg/m2) <2544151.4 (11.1)133.3 (16.3)46150.2 (11.2)143.6 (18.1)−11.0 (−17.7 to −4.4) ≥2580150.3 (10.3)132.7 (14.1)71152.4 (11.0)144.2 (17.9)−10.4 (−15.3 to −5.5)Drinking status Current non-drinker46151.7 (11.6)130.4 (14.3)46153.6 (12.1)144.7 (19.4)−13.4 (−20.2 to −6.6) Current drinker78150.0 (9.9)134.4 (15.0)71150.1 (10.2)143.4 (17.0)−9.0 (−13.7 to −4.2)Smoking status Non-smoker61151.5 (11.6)131.5 (14.5)59151.8 (11.6)141.8 (19.5)−10.1 (−15.9 to −4.4) Current smoker24150.7 (8.5)133.9 (17.2)21151.5 (10.3)146.0 (15.3)−12.1 (−22.1 to −2.1) Ex-smoker39149.3 (10.1)134.6 (14.0)37151.2 (11.0)146.2 (16.5)−10.3 (−16.6 to −4.0)Duration of essential hypertension (years) <555149.5 (9.5)131.3 (14.8)48149.3 (10.5)141.3 (16.0)−10.0 (−15.8 to −4.3) ≥5, <1017149.3 (11.9)130.0 (18.7)23153.2 (11.3)144.9 (17.2)−11.9 (−22.2 to −1.6) ≥1052152.3 (11.1)135.6 (13.3)46153.0 (11.5)146.3 (20.0)−10.3 (−16.8 to −3.9)SBP at baseline (mmHg) <14761142.0 (3.8)129.4 (13.8)55142.5 (3.6)136.5 (14.5)−6.8 (−12.0 to −1.6) ≥14763159.0 (7.9)136.4 (15.1)62159.5 (9.2)150.6 (18.1)−14.0 (−19.8 to −8.2)DBP at baseline (mmHg) <9364148.7 (10.7)133.7 (15.6)53148.1 (9.8)142.3 (15.3)−8.9 (−14.1 to −3.7) ≥9360152.7 (10.0)132.1 (14.1)64154.3 (11.4)145.3 (19.8)−12.5 (−18.4 to −6.5)Diabetes mellitus Yes29153.7 (10.7)138.7 (15.3)27150.6 (11.8)140.9 (19.6)−3.7 (−12.8 to 5.4) No95149.7 (10.4)131.2 (14.3)90151.8 (10.9)144.8 (17.4)−12.5 (−16.9 to −8.2)Dyslipidemia Yes73150.7 (11.6)132.1 (14.2)73150.1 (11.0)141.2 (16.8)−9.3 (−14.1 to −4.4) No51150.6 (8.9)134.1 (15.8)44153.9 (11.0)148.6 (19.0)−12.2 (−18.9 to −5.6)Chronic kidney disease Yes63152.0 (11.7)134.6 (15.1)57151.4 (11.1)144.9 (19.4)−10.7 (−16.6 to −4.7) No61149.2 (9.1)131.3 (14.5)60151.7 (11.1)143.0 (16.5)−10.4 (−15.7 to −5.1)Coronary artery disease Yes22151.0 (12.0)132.1 (11.3)20146.1 (11.0)142.2 (14.8)−11.7 (−19.7 to −3.7) No102150.6 (10.3)133.1 (15.6)97152.6 (10.8)144.3 (18.5)−10.0 (−14.5 to −5.5)Notes: Values are presented as the mean (SD). aNo significant interaction effects were observed for subgroups of baseline factor. bTesting for difference between treatment groups (ANCOVA model with baseline SiSBP as a covariate). cBMI (kg/m²) = weight (kg) / (height (cm) / 100)².Abbreviations: SiSBP, sitting systolic blood pressure; FMS, fimasartan; IND, indapamide sustained release; LS, least square; CI, confidence interval; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; SD, standard deviation; ANCOVA, analysis of covariance. Change in SiSBP From Baseline to week 8 According to Subgroup Analyses (Full Analysis Set) Notes: Values are presented as the mean (SD). aNo significant interaction effects were observed for subgroups of baseline factor. bTesting for difference between treatment groups (ANCOVA model with baseline SiSBP as a covariate). cBMI (kg/m²) = weight (kg) / (height (cm) / 100)². Abbreviations: SiSBP, sitting systolic blood pressure; FMS, fimasartan; IND, indapamide sustained release; LS, least square; CI, confidence interval; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; SD, standard deviation; ANCOVA, analysis of covariance. Forest plot of subgroup analyses for comparison of FMS/IND combination therapy and FMS monotherapy of the changes in SiSBP from baseline to week 8. Safety and Tolerability Among 244 patients in the safety set, 15.98% of patients experienced at least one TEAE (Table 4). The incidence of TEAEs was 17.74% in the FMS/IND SR and 14.17% in the FMS (P = 0.4461). The most frequently reported TEAE was dizziness (4.10%), followed by postural dizziness (1.64%), headache (1.23%) and hypokalemia (0.82%). Hyponatremia, although not among the most frequently reported TEAEs, was observed in only one patient in the FMS/IND SR. There was also no significant difference in each incidence of all TEAEs between the two groups. One patient in the FMS/IND SR experienced mechanical ileus, which was not related to the study drug. Furthermore, 9.02% of patients experienced at least one ADR. There was no statistically significant difference in ADRs between the two groups. No serious ADR was reported during the study period. Differences in the study drug discontinuation due to TEAEs and ADRs were not significant between groups. Subgroup analysis of patients aged 65 and older showed no statistically significant differences in TEAEs and ADRs between groups and similar results were observed in the patients under 65 years old (Table 5).Table 4Summary of TEAEs and ADRsVariableFMS/IND(N=124)FMS(N=120)P-valueaPatients with TEAEs22 (17.74)17 (14.17)0.4461 Severity Mild2622 Moderate41 Severe00Patients with TEAEs leading to drug discontinuation6 (4.84)2 (1.67)0.2814Patients with serious TEAEsb1 (0.81)0 (0.00)1.0000Incidence of TEAEs ≥ 1% in each treatment group Dizziness7 (5.65)3 (2.50)0.3341 Dizziness postural4 (3.23)0 (0.00)0.1221 Headache1 (0.81)2 (1.67)0.6173 Hypokalemia2 (1.61)0 (0.00)0.4981Patients with ADRs15 (12.10)7 (5.83)0.0877Patients with ADRs leading to drug discontinuation4 (3.23)1 (0.83)0.3702Patients with serious ADRs0 (0.00)0 (0.00)-Notes: Severity is displayed as “number of events” and others are displayed as “number of participants (percentage of participants)”. aTesting for difference between treatment groups (chi-square test or Fisher’s exact test). bA serious TEAE that occurred in the FMS/IND was mechanical ileus. Causal relationship was assessed as “not related” by an investigator.Abbreviations: TEAEs, treatment-emergent adverse events; ADRs, adverse drug reactions; FMS, fimasartan; IND, indapamide sustained release. Table 5Summary of TEAEs and ADRs by AgeSubgroup (Years)Age Group ≥ 65Age Group < 65VariableFMS/IND(N=58)FMS(N=63)P-valueaFMS/IND(N=66)FMS(N=57)P-valueaPatients with TEAEs12 (20.69)6 (9.52)0.084710 (15.15)11 (19.30)0.5422 Severity Mild177915 Moderate1031 Severe0000Patients with TEAEs leading to drug discontinuation3 (5.17)1 (1.59)0.34893 (4.55)1 (1.75)0.6229Patients with serious TEAEs0 (0.00)0 (0.00)-1 (1.52)0 (0.00)1.0000Incidence of TEAEs ≥ 2% in each treatment group Dizziness6 (10.34)3 (4.76)0.30881 (1.52)0 (0.00)1.0000 Dizziness postural2 (3.45)0 (0.00)0.22772 (3.03)0 (0.00)0.4986 Headache0 (0.00)0 (0.00)-1 (1.52)2 (3.51)0.5960 Hypokalemia0 (0.00)0 (0.00)-2 (3.03)0 (0.00)0.4986Patients with ADRs8 (13.79)3 (4.76)0.08437 (10.61)4 (7.02)0.4868Patients with ADRs leading to drug discontinuation2 (3.45)0 (0.00)0.22772 (3.03)1 (1.75)1.0000Patients with serious ADRs0 (0.00)0 (0.00)-0 (0.00)0 (0.00)-Notes: Severity is displayed as “number of events” and others are displayed as “number of participants (percentage of participants)”. aTesting for difference between-treatment groups (chi-square test or Fisher’s exact test).Abbreviations: TEAEs, treatment-emergent adverse events; ADRs, adverse drug reactions; FMS, fimasartan; IND, indapamide sustained release. Table 4Summary of TEAEs and ADRsVariableFMS/IND(N=124)FMS(N=120)P-valueaPatients with TEAEs22 (17.74)17 (14.17)0.4461 Severity Mild2622 Moderate41 Severe00Patients with TEAEs leading to drug discontinuation6 (4.84)2 (1.67)0.2814Patients with serious TEAEsb1 (0.81)0 (0.00)1.0000Incidence of TEAEs ≥ 1% in each treatment group Dizziness7 (5.65)3 (2.50)0.3341 Dizziness postural4 (3.23)0 (0.00)0.1221 Headache1 (0.81)2 (1.67)0.6173 Hypokalemia2 (1.61)0 (0.00)0.4981Patients with ADRs15 (12.10)7 (5.83)0.0877Patients with ADRs leading to drug discontinuation4 (3.23)1 (0.83)0.3702Patients with serious ADRs0 (0.00)0 (0.00)-Notes: Severity is displayed as “number of events” and others are displayed as “number of participants (percentage of participants)”. aTesting for difference between treatment groups (chi-square test or Fisher’s exact test). bA serious TEAE that occurred in the FMS/IND was mechanical ileus. Causal relationship was assessed as “not related” by an investigator.Abbreviations: TEAEs, treatment-emergent adverse events; ADRs, adverse drug reactions; FMS, fimasartan; IND, indapamide sustained release. Summary of TEAEs and ADRs Notes: Severity is displayed as “number of events” and others are displayed as “number of participants (percentage of participants)”. aTesting for difference between treatment groups (chi-square test or Fisher’s exact test). bA serious TEAE that occurred in the FMS/IND was mechanical ileus. Causal relationship was assessed as “not related” by an investigator. Abbreviations: TEAEs, treatment-emergent adverse events; ADRs, adverse drug reactions; FMS, fimasartan; IND, indapamide sustained release. Table 5Summary of TEAEs and ADRs by AgeSubgroup (Years)Age Group ≥ 65Age Group < 65VariableFMS/IND(N=58)FMS(N=63)P-valueaFMS/IND(N=66)FMS(N=57)P-valueaPatients with TEAEs12 (20.69)6 (9.52)0.084710 (15.15)11 (19.30)0.5422 Severity Mild177915 Moderate1031 Severe0000Patients with TEAEs leading to drug discontinuation3 (5.17)1 (1.59)0.34893 (4.55)1 (1.75)0.6229Patients with serious TEAEs0 (0.00)0 (0.00)-1 (1.52)0 (0.00)1.0000Incidence of TEAEs ≥ 2% in each treatment group Dizziness6 (10.34)3 (4.76)0.30881 (1.52)0 (0.00)1.0000 Dizziness postural2 (3.45)0 (0.00)0.22772 (3.03)0 (0.00)0.4986 Headache0 (0.00)0 (0.00)-1 (1.52)2 (3.51)0.5960 Hypokalemia0 (0.00)0 (0.00)-2 (3.03)0 (0.00)0.4986Patients with ADRs8 (13.79)3 (4.76)0.08437 (10.61)4 (7.02)0.4868Patients with ADRs leading to drug discontinuation2 (3.45)0 (0.00)0.22772 (3.03)1 (1.75)1.0000Patients with serious ADRs0 (0.00)0 (0.00)-0 (0.00)0 (0.00)-Notes: Severity is displayed as “number of events” and others are displayed as “number of participants (percentage of participants)”. aTesting for difference between-treatment groups (chi-square test or Fisher’s exact test).Abbreviations: TEAEs, treatment-emergent adverse events; ADRs, adverse drug reactions; FMS, fimasartan; IND, indapamide sustained release. Summary of TEAEs and ADRs by Age Notes: Severity is displayed as “number of events” and others are displayed as “number of participants (percentage of participants)”. aTesting for difference between-treatment groups (chi-square test or Fisher’s exact test). Abbreviations: TEAEs, treatment-emergent adverse events; ADRs, adverse drug reactions; FMS, fimasartan; IND, indapamide sustained release. Additionally, both groups’ laboratory test results for renal function and electrolyte levels exhibited only slight variations and stayed within the typical reference limits (Table 6).Table 6Changes in Laboratory Tests Values of Renal Function and Electrolyte From Baseline to week 8VariableFMS/IND(N=124)FMS(N=120)P-valueaSerum creatinine, mg/dL Baseline0.86 (0.18)0.87 (0.21) Week 80.94 (0.44)0.87 (0.18) Change from baseline to week 80.08 (0.39)0.00 (0.08)0.0013 P-valueb< 0.00010.4420Serum uric acid, mg/dL Baseline5.53 (1.37)6.03 (1.62) Week 86.23 (1.75)5.93 (1.45) Change from baseline to week 80.73 (0.99)−0.09 (0.94)< 0.0001 P-valueb< 0.00010.7557Serum sodium, mmol/L Baseline139.80 (2.34)140.10 (2.08) Week 8139.18 (2.32)139.90 (1.94) Change from baseline to week 8−0.72 (2.18)−0.29 (1.85)0.0754 P-valueb0.00030.0735Serum potassium, mmol/L Baseline4.41 (0.39)4.40 (0.36) Week 84.30 (0.39)4.39 (0.37) Change from baseline to week 8−0.12 (0.38)−0.01 (0.38)0.0380 P-valueb0.00130.7522eGFRc, mL/min/1.73m2 Baseline87.78 (16.44)87.91 (15.28) Week 884.41 (17.48)86.99 (14.61) Change from baseline to week 8−3.53 (7.92)−0.59 (6.41)0.0050 P-valueb< 0.00010.3271Notes: Values are presented as the mean (SD). Baseline is the last observed value prior to the first dose of study intervention. aTesting for difference between treatment groups (two sample t-test or Wilcoxon rank sum test). bTesting for change within group (paired t-test or Wilcoxon signed rank test). ceGFR was calculated using the CKD-EPI equation.Abbreviations: FMS, fimasartan; IND, indapamide sustained release; eGFR, estimated glomerular filtration rate; SD, standard deviation. Table 6Changes in Laboratory Tests Values of Renal Function and Electrolyte From Baseline to week 8VariableFMS/IND(N=124)FMS(N=120)P-valueaSerum creatinine, mg/dL Baseline0.86 (0.18)0.87 (0.21) Week 80.94 (0.44)0.87 (0.18) Change from baseline to week 80.08 (0.39)0.00 (0.08)0.0013 P-valueb< 0.00010.4420Serum uric acid, mg/dL Baseline5.53 (1.37)6.03 (1.62) Week 86.23 (1.75)5.93 (1.45) Change from baseline to week 80.73 (0.99)−0.09 (0.94)< 0.0001 P-valueb< 0.00010.7557Serum sodium, mmol/L Baseline139.80 (2.34)140.10 (2.08) Week 8139.18 (2.32)139.90 (1.94) Change from baseline to week 8−0.72 (2.18)−0.29 (1.85)0.0754 P-valueb0.00030.0735Serum potassium, mmol/L Baseline4.41 (0.39)4.40 (0.36) Week 84.30 (0.39)4.39 (0.37) Change from baseline to week 8−0.12 (0.38)−0.01 (0.38)0.0380 P-valueb0.00130.7522eGFRc, mL/min/1.73m2 Baseline87.78 (16.44)87.91 (15.28) Week 884.41 (17.48)86.99 (14.61) Change from baseline to week 8−3.53 (7.92)−0.59 (6.41)0.0050 P-valueb< 0.00010.3271Notes: Values are presented as the mean (SD). Baseline is the last observed value prior to the first dose of study intervention. aTesting for difference between treatment groups (two sample t-test or Wilcoxon rank sum test). bTesting for change within group (paired t-test or Wilcoxon signed rank test). ceGFR was calculated using the CKD-EPI equation.Abbreviations: FMS, fimasartan; IND, indapamide sustained release; eGFR, estimated glomerular filtration rate; SD, standard deviation. Changes in Laboratory Tests Values of Renal Function and Electrolyte From Baseline to week 8 Notes: Values are presented as the mean (SD). Baseline is the last observed value prior to the first dose of study intervention. aTesting for difference between treatment groups (two sample t-test or Wilcoxon rank sum test). bTesting for change within group (paired t-test or Wilcoxon signed rank test). ceGFR was calculated using the CKD-EPI equation. Abbreviations: FMS, fimasartan; IND, indapamide sustained release; eGFR, estimated glomerular filtration rate; SD, standard deviation. Discussion This trial demonstrated that combination therapy with FMS and IND SR was significantly more effective than FMS monotherapy in lowering BP among patients with essential hypertension inadequately controlled with FMS 30 mg. The combination therapy resulted in greater reductions in both SiSBP and SiDBP as early as week 4, with this effect persisting through week 8, without compromising safety. At week 8, the LS mean reduction in SiSBP was −17.9 mmHg in the FMS/IND SR and −7.4 mmHg in the FMS, yielding an LS mean difference of −10.5 mmHg. Moreover, the BP control rates and response rates were approximately twice as high in the combination group. Notably, the FMS 30 mg/IND SR 1.5 mg combination achieved more rapid BP reduction at week 4 than FMS 60 mg monotherapy achieved by week 8, underscoring the clinical advantage of early combination therapy. These findings are consistent with previous studies demonstrating that low- to standard-dose dual combination therapy is more effective than standard-dose monotherapy in reducing BP, without increasing the rate of discontinuation due to AEs.39 IND, a thiazide-like diuretic, has been shown to exert a longer duration of action and a more potent BP-lowering effect than HCTZ, and its efficacy is comparable to that of chlorthalidone.11,12,21 However, prior studies have associated both chlorthalidone and the IR formulation of IND with a higher incidence of electrolyte disturbances, including hypokalemia and hyponatremia.13,22 In this context, the present findings suggest that the FMS/IND SR combination may successfully balance efficacy and safety. IND promotes natriuresis and reduces plasma volume, while FMS counteracts diuretic-induced RAAS activation and mitigates associated hypokalemia.9,20 Furthermore, the SR formulation of IND was specifically designed to achieve more stable plasma concentrations and reduce peak-related metabolic AEs.29 Consistent with this rationale, the present trial showed that FMS/IND SR produced greater BP reduction than FMS monotherapy, with a comparable tolerability profile over 8 weeks. Importantly, nearly half of the study population consisted of patients aged 65 years or older. Subgroup analyses revealed that both the antihypertensive efficacy and safety profile of FMS/IND SR were consistent in this older cohort. Although elderly patients with hypertension are at increased risk for electrolyte abnormalities such as hypokalemia,40 no such TEAEs were observed in this subgroup. Furthermore, intensive BP reduction and antihypertensive therapy are frequently associated with dizziness in older adults.41–43 Despite the greater BP reduction observed in the combination group, the incidence of dizziness did not differ significantly between groups, reinforcing the favorable tolerability of this regimen in elderly populations. These findings align with previous study, which demonstrated that IND SR is both effective and well-tolerated in older adults.24 Taken together, these results support the use of FMS/IND SR as a particularly suitable option in elderly patients with salt-sensitive hypertension. Beyond age, the efficacy of the FMS/IND SR combination in reducing SiSBP was consistently observed across all other subgroups, regardless of baseline characteristics. This suggests that FMS/IND SR may be a broadly effective therapeutic option for patients whose BP is inadequately controlled with FMS monotherapy. Given its favorable efficacy and safety profile, IND SR may represent a promising alternative to conventional diuretic components in ARB-based combination therapies. In line with current hypertension guidelines that increasingly advocate early combination therapy, this trial provides important clinical evidence supporting ARB-thiazide-like diuretic combinations. Unlike hydrochlorothiazide, indapamide SR offers stable pharmacokinetics and lower metabolic risk, while maintaining potent antihypertensive efficacy. The superior efficacy and favorable tolerability of FMS/IND SR in this trial, including elderly patients at high risk for electrolyte abnormalities, highlight its potential as a novel and clinically relevant alternative to conventional ARB-diuretic regimens. In addition, both agents have individually demonstrated cardiovascular and renal protective benefits in high-risk populations.29–32,44–50 Therefore, these data support the potential of the FMS/IND SR combination as a comprehensive treatment strategy for hypertension in high-risk individuals. Further long-term studies are warranted to evaluate its impact on cardiovascular and renal outcomes in this population. There are some limitations in this study. First, although the 8-week treatment period was sufficient to assess short-term antihypertensive efficacy and early tolerability, it was not long enough to evaluate long-term safety, metabolic effects, renal outcomes, or cardiovascular endpoints. Accordingly, the present findings should be interpreted as evidence of short-term efficacy and tolerability rather than long-term clinical effectiveness. Second, the sample size was relatively small, which may have limited the ability to fully characterize the tolerability profile and detect uncommon AEs. Third, no direct comparison with other established ARB–diuretic combinations was performed; therefore, the present results should not be interpreted as demonstrating comparative clinical effectiveness versus HCTZ- or chlorthalidone-based regimens. Lastly, all participants were Koreans thus the generalization of the results to patients outside of this population would be difficult. Conclusion The FINEDUO study was the first clinical trial to evaluate the BP-lowering efficacy and tolerability of FMS/IND SR combination therapy in patients with essential hypertension inadequately controlled with FMS monotherapy. The combination regimen demonstrated superior antihypertensive efficacy in this population, with a safety profile comparable to that of FMS monotherapy. Notably, FMS/IND SR maintained robust BP-lowering effects while minimizing AEs such as electrolyte disturbances, even in elderly patients at elevated risk for metabolic complications. These findings support FMS/IND SR as an effective treatment option in patients with essential hypertension inadequately controlled with FMS monotherapy. Further longer-term and head-to-head studies are needed to define its safety and comparative clinical effectiveness relative to other ARB–diuretic regimens.